Cell-Penetrating Peptides-Mediated Therapeutic Agents Delivery into the Central Nervous System
Source abstract
Abstract
There has been a significant increase in the prevalence of central nervous system (CNS) disorders, resulting in a considerable decrease in the overall well-being for affected individuals. Moreover, the therapeutic effectiveness of CNS diseases is greatly impeded by the inability of the majority of small molecule drugs and almost all large molecule drugs to penetrate the brain barrier. Therefore, it is crucial to develop an efficient drug delivery system to effectively treat CNS disorders by transporting therapeutic agents to the CNS. Cell-penetrating peptides (CPPs), which are well-known for their efficient membrane penetration capabilities and their ability to facilitate the rapid passage of therapeutic drugs across the brain barrier, offer a potential strategy for the transportation of macromolecules across the brain barrier. This study has provided a comprehensive overview of the utilization of CPP-mediated therapeutic agents in the management of CNS diseases and summarized the recent advancements in clinic, aiming to establish a scientific foundation for the application of CPPs in the treatment of CNS diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Extracellular vesicles in disease · MicroRNA in disease regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Cixi Biomedical Research Institute, Wenzhou Medical University, Cixi 315300, China
Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Chinese Academy of Sciences (CAS) Key Laboratory of Magnetic Materials and Devices, Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo 315201, China
Zhejiang International Cooperation Base of Biomedical Materials Technology and Application, Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Cixi Institute of Biomedical Engineering, Cixi 315300, China
Funding
National Key Research and Development Program of China · Ningbo Municipal Bureau of Science and Technology · Youth Innovation Promotion Association of the Chinese Academy of Sciences · Key Research and Development Program of Zhejiang Province · National Natural Science Foundation of China
References (100+)
Show source-provided references
1. 10.1016/j.stem.2023.03.01710.1016/j.stem.2023.03.017 ↗
2. 10.1016/j.arr.2023.10207010.1016/j.arr.2023.102070 ↗
3. Global status report on the public health response to dementia. World Health Organization, Geneva; 2021. License: CC BY-NC-SA 3.0 IGO. Retrieved from https://iris.who.int/bitstream/handle/10665/344701/9789240033245-eng.pdf?sequence=1.(Accessed: 2023–09–05).
4. 10.1038/s41582-023-00794-210.1038/s41582-023-00794-2 ↗
5. 10.1016/j.mattod.2020.02.00110.1016/j.mattod.2020.02.001 ↗
6. 10.1038/s41392-023-01481-w10.1038/s41392-023-01481-w ↗
7. 10.1038/d41573-023-00106-910.1038/d41573-023-00106-9 ↗
8. 10.1016/j.tips.2017.01.00310.1016/j.tips.2017.01.003 ↗
9. 10.3390/biom901002210.3390/biom9010022 ↗
10. 10.1186/s12987-020-00230-310.1186/s12987-020-00230-3 ↗
11. 10.1016/j.brainresbull.2022.09.01710.1016/j.brainresbull.2022.09.017 ↗
12. 10.2967/jnumed.119.23719810.2967/jnumed.119.237198 ↗
13. 10.3390/ijms2201024610.3390/ijms22010246 ↗
14. 10.1038/s41593-022-01240-010.1038/s41593-022-01240-0 ↗
15. 10.1016/bs.apha.2014.06.00910.1016/bs.apha.2014.06.009 ↗
16. 10.1007/s11095-021-03006-y10.1007/s11095-021-03006-y ↗
17. 10.1007/s12035-019-1565-710.1007/s12035-019-1565-7 ↗
18. 10.3390/ph1606081010.3390/ph16060810 ↗
19. 10.1038/s41573-021-00139-y10.1038/s41573-021-00139-y ↗
20. 10.1016/j.drudis.2023.10373510.1016/j.drudis.2023.103735 ↗
21. 10.1038/s41467-023-39326-310.1038/s41467-023-39326-3 ↗
22. 10.1186/s12987-020-00196-210.1186/s12987-020-00196-2 ↗
23. 10.1517/17425247.2016.117131510.1517/17425247.2016.1171315 ↗
24. 10.1083/jcb.20141214710.1083/jcb.201412147 ↗
25. 10.1016/S0304-3940(01)01927-910.1016/S0304-3940(01)01927-9 ↗
26. 10.1186/2045-8118-8-310.1186/2045-8118-8-3 ↗
27. 10.1016/j.bbi.2016.03.01010.1016/j.bbi.2016.03.010 ↗
28. 10.1186/2045-8118-8-710.1186/2045-8118-8-7 ↗
29. 10.1007/978-1-60761-938-3_410.1007/978-1-60761-938-3_4 ↗
30. Johnson, K. S.; Sexton, D. J. Cerebrospinal fluid: physiology and utility of an examination in disease states. Calderwood, S. W., Ed. UpToDate 2011, 19. Retrieved from https://medilib.ir/uptodate/show/1285. (Accessed: 2023–09–05).
31. 10.3389/fnagi.2023.117998810.3389/fnagi.2023.1179988 ↗
32. 10.1016/j.tins.2020.04.00310.1016/j.tins.2020.04.003 ↗
33. 10.1186/2045-8118-11-1010.1186/2045-8118-11-10 ↗
34. 10.29245/2572.942X/2018/4.119410.29245/2572.942X/2018/4.1194 ↗
35. 10.1242/jcs.12452910.1242/jcs.124529 ↗
36. 10.1186/2045-8118-9-1510.1186/2045-8118-9-15 ↗
37. 10.1016/j.neuroscience.2008.06.01510.1016/j.neuroscience.2008.06.015 ↗
38. 10.1007/978-3-319-96445-4_1410.1007/978-3-319-96445-4_14 ↗
39. 10.1016/j.drup.2015.02.00210.1016/j.drup.2015.02.002 ↗
40. 10.1038/ncomms519610.1038/ncomms5196 ↗
41. 10.2174/138920372266621092015181010.2174/1389203722666210920151810 ↗
42. 10.1093/neuonc/5.2.7910.1093/neuonc/5.2.79 ↗
43. 10.1016/j.bbrc.2018.02.14910.1016/j.bbrc.2018.02.149 ↗
44. 10.3390/pharmaceutics703017510.3390/pharmaceutics7030175 ↗
45. 10.1016/0092-8674(88)90262-010.1016/0092-8674(88)90262-0 ↗
46. 10.1038/s41419-023-05672-910.1038/s41419-023-05672-9 ↗
47. 10.1038/s41598-020-80889-810.1038/s41598-020-80889-8 ↗
48. 10.1007/s00401-021-02268-510.1007/s00401-021-02268-5 ↗
49. 10.1007/s00702-009-0226-910.1007/s00702-009-0226-9 ↗
50. 10.1016/j.jneuroim.2015.08.00510.1016/j.jneuroim.2015.08.005 ↗
51. 10.1080/1061186X.2021.192705510.1080/1061186X.2021.1927055 ↗
52. 10.1080/21688370.2019.165115710.1080/21688370.2019.1651157 ↗
53. 10.3390/ijms24131073910.3390/ijms241310739 ↗
54. 10.1111/cns.1319010.1111/cns.13190 ↗
55. 10.1002/mabi.20190042510.1002/mabi.201900425 ↗
56. 10.1002/wnan.169510.1002/wnan.1695 ↗
57. 10.1186/s12951-021-01002-310.1186/s12951-021-01002-3 ↗
58. 10.1016/j.apsb.2016.04.00110.1016/j.apsb.2016.04.001 ↗
59. 10.3389/fphar.2022.106849510.3389/fphar.2022.1068495 ↗
60. 10.1074/jbc.272.25.1601010.1074/jbc.272.25.16010 ↗
61. 10.1039/D0BM01755H10.1039/D0BM01755H ↗
62. 10.1186/s13052-018-0563-010.1186/s13052-018-0563-0 ↗
63. 10.1016/j.molmed.2012.04.01210.1016/j.molmed.2012.04.012 ↗
64. 10.1016/j.peptides.2014.04.01510.1016/j.peptides.2014.04.015 ↗
65. 10.3390/biomedicines1107197110.3390/biomedicines11071971 ↗
66. 10.1016/j.jconrel.2014.11.00410.1016/j.jconrel.2014.11.004 ↗
67. 10.3390/pharmaceutics1202009310.3390/pharmaceutics12020093 ↗
68. 10.18632/oncotarget.2644210.18632/oncotarget.26442 ↗
69. 10.1016/j.molmed.2015.06.00510.1016/j.molmed.2015.06.005 ↗
70. 10.1016/j.redox.2020.10183910.1016/j.redox.2020.101839 ↗
71. 10.1101/2022.06.24.49747510.1101/2022.06.24.497475 ↗
72. 10.3390/ijms2405427710.3390/ijms24054277 ↗
73. 10.1038/s41418-018-0116-510.1038/s41418-018-0116-5 ↗
74. 10.1096/fj.12-22258810.1096/fj.12-222588 ↗
75. 10.1016/j.abb.2014.10.00910.1016/j.abb.2014.10.009 ↗
76. 10.1016/j.bbamem.2007.09.03410.1016/j.bbamem.2007.09.034 ↗
77. 10.3390/biomedicines1103072810.3390/biomedicines11030728 ↗
78. 10.1111/acel.1303110.1111/acel.13031 ↗
79. 10.1016/j.redox.2020.10183910.1016/j.redox.2020.101839 ↗
80. 10.1016/j.jconrel.2014.05.04010.1016/j.jconrel.2014.05.040 ↗
81. 10.1093/rb/rbu01710.1093/rb/rbu017 ↗
82. 10.1248/bpb.b17-0084810.1248/bpb.b17-00848 ↗
83. 10.1016/j.jconrel.2021.06.00710.1016/j.jconrel.2021.06.007 ↗
84. 10.1007/s13346-022-01117-610.1007/s13346-022-01117-6 ↗
85. 10.1038/s12276-018-0124-z10.1038/s12276-018-0124-z ↗
86. 10.3390/pharmaceutics1308113410.3390/pharmaceutics13081134 ↗
87. 10.1007/s10989-019-09971-810.1007/s10989-019-09971-8 ↗
88. 10.1172/jci.insight.16051610.1172/jci.insight.160516 ↗
89. 10.1016/j.ijpharm.2019.11878910.1016/j.ijpharm.2019.118789 ↗
90. 10.1002/cbin.1116110.1002/cbin.11161 ↗
91. 10.1038/srep0898610.1038/srep08986 ↗
92. 10.1073/pnas.160573111310.1073/pnas.1605731113 ↗
93. 10.1021/acsnano.3c0149710.1021/acsnano.3c01497 ↗
94. 10.1021/acs.molpharmaceut.0c0123810.1021/acs.molpharmaceut.0c01238 ↗
95. 10.2174/138955752066620051312235710.2174/1389557520666200513122357 ↗
96. 10.1016/j.addr.2021.11383410.1016/j.addr.2021.113834 ↗
97. 10.3389/fphar.2020.0069710.3389/fphar.2020.00697 ↗
98. 10.1089/nat.2018.074710.1089/nat.2018.0747 ↗
99. 10.1080/15476286.2022.206633410.1080/15476286.2022.2066334 ↗
100. 10.1007/s11095-022-03433-510.1007/s11095-022-03433-5 ↗